AI assistant
ENDRA Life Sciences Inc. — Director's Dealing 2020
May 29, 2020
35444_dirs_2020-05-29_b71a7304-7f58-49eb-bdf7-33102911b053.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2020-05-28
Reporting Person: DIGIANDOMENICO ANTHONY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-28 | Common Stock | P | 5000 | $0.90 | Acquired | 276509 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.88 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Includes unvested restricted stock units.
F3: The balance reflects an adjustment to correct a computational error in column 5 of the reporting person's Form 4 filed December 11, 2019, which stated 199,226 but should have stated 218,652.